Gambrelle J, Mauget Faÿsse M, Quaranta El-Maftouhi M, Grange J D
Service d'Ophtalmologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon.
J Fr Ophtalmol. 2008 Jan;31(1):31-5. doi: 10.1016/s0181-5512(08)70327-9.
Choroidal nevi are the most common benign intraocular tumors. However, the occurrence of subretinal neovascularization secondary to choroidal nevus is very rare. Our goal was to assess the efficacy and the safety of photodynamic therapy (PDT) for treatment of subretinal neovascularization related to choroidal nevi.
We conducted a retrospective study including subretinal neovascularization secondary to choroidal nevi treated by PDT from 1999 to 2005. PDT was performed according to the standard protocols used for treating neovascularization due to age-related macular degeneration (ARMD). Post-PDT follow-up was also done according to the guidelines used in ARMD. Moreover, tumors were followed up every 3 months.
Six subretinal neovascularizations secondary to choroidal nevi were included in our study. All nevi were localized in the posterior choroids. The median diameter of tumors was 3mm and their thickness was less than 2mm in all cases. Subretinal neovascularizations were classic in five cases. The last case was a small vascularized pigment epithelium detachment. Locations were subfoveal in two cases, juxtafoveal in three cases, and extrafoveal in one case. In half the cases, the size of subretinal neovascularization was 1-disk-diameter or less. A mean of 3.3 sessions of PDT were necessary to obtain the stabilization of subretinal neovascularization on both fluorescein angiography and OCT. The average follow-up period was 35 months with no patients lost to follow-up. Visual outcomes were extremely variable. Large or subfoveal neovascularization but also a history of atrophic ARMD were related to worse functional results. No growth of the nevi was observed.
Subretinal neovascularization is reassuring from the oncologist's point of view because it is considered a relative indicator of benignity of the nevus. However, it often marks a definitive turning point in visual function. PDT appears to be a safe and effective procedure for the treatment subretinal neovascularization secondary to choroidal nevus, with results similar to those observed in ARMD.
脉络膜痣是最常见的眼内良性肿瘤。然而,继发于脉络膜痣的视网膜下新生血管形成非常罕见。我们的目标是评估光动力疗法(PDT)治疗与脉络膜痣相关的视网膜下新生血管形成的疗效和安全性。
我们进行了一项回顾性研究,纳入了1999年至2005年接受PDT治疗的继发于脉络膜痣的视网膜下新生血管形成患者。PDT按照用于治疗年龄相关性黄斑变性(ARMD)所致新生血管形成的标准方案进行。PDT术后随访也按照ARMD的指南进行。此外,每3个月对肿瘤进行一次随访。
我们的研究纳入了6例继发于脉络膜痣的视网膜下新生血管形成患者。所有痣均位于脉络膜后部。所有病例中肿瘤的中位直径为3mm,厚度小于2mm。5例视网膜下新生血管形成是典型的。最后1例是小的血管化色素上皮脱离。位置为黄斑中心凹下2例,黄斑中心凹旁3例,黄斑中心凹外1例。半数病例中,视网膜下新生血管形成的大小为1个视盘直径或更小。平均需要3.3次PDT治疗才能使视网膜下新生血管形成在荧光素血管造影和光学相干断层扫描(OCT)上均达到稳定。平均随访期为35个月,无患者失访。视觉结果差异极大。大的或黄斑中心凹下的新生血管形成以及萎缩性ARMD病史与较差的功能结果相关。未观察到痣的生长。
从肿瘤学家的角度来看,视网膜下新生血管形成令人放心,因为它被认为是痣良性的相对指标。然而,它通常标志着视觉功能的一个决定性转折点。PDT似乎是治疗继发于脉络膜痣的视网膜下新生血管形成的一种安全有效的方法,其结果与ARMD中观察到的结果相似。